RFK Jr threatens publishing ban for government scientists

29 May 2025

Health and Human Services Secretary Robert F Kennedy Jr has said he may prohibit researchers at government institutions from submitting their work to major medical journals, raising fresh tensions between the federal agency and the broader scientific community.

Speaking Tuesday, Kennedy floated the idea of establishing alternative, government-run journals in place of established titles. He said the potential ban would apply to publications seen as influential, including The Lancet, New England Journal of Medicine, and JAMA, which he criticized as being under the sway of commercial interests.

The move would mark a significant shift in federal research policy and deepen the Trump administration’s pattern of clashes with long-standing scientific institutions. Kennedy said the aim was to provide platforms for “legitimate” science, arguing that current publications are compromised by industry ties.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical